Latest News and Press Releases

CDR-Life today announced the advancement of the Phase 1 study with BI 771716, its therapeutic candidate in partnership with Boehringer Ingelheim.

CDR-Life Inc. today announced a presentation at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts.

CDR-Life today announced the presentation of results on T-cell engagers targeting hard-to-treat solid tumors at the AACR Annual Meeting 2024.

ZURICH, Switzerland, Jan. 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA)...

ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic...

Therapeutic potential of CDR404, as a first-of-its-kind precision immunotherapy for HLA-A*02:01+ patients with MAGE-A4+ squamous non-small cell lung carcinoma (SQ-NSCLC) Development of a Quantitative...

 - CDR404 represents a potential paradigm shift in the development of T-cell engagers for solid cancers  - Epithelial cancer indications eligible for CDR404 Phase 1 trial include non-small cell...

ZÜRICH, Switzerland, Aug. 02, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a milestone payment triggered by the achievement of a development milestone with a partnered antibody...

ZÜRICH, Switzerland, Dec. 08, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-selective immuno-oncology therapeutics...

ZÜRICH, Switzerland, Nov. 01, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-selective immuno-oncology therapeutics...